Home / 2021 / June / 07

Daily Archives: June 7, 2021

UPDATE – UCSF QBI and University College, London Identify Mutations in “U.K.” Strain of Coronavirus SARS-CoV-2 Responsible for Enhanced Transmissibility and Infectivity

– Findings show key mutations and evolution of U.K. SARS-CoV-2 compared to earlier lineages account for upregulation of innate immune antagonists, which hamper immune response and allow for increased viral replication and duration of infection –

SAN FRANCISCO, Calif. and LONDON, June 07, 2021 (GLOBE NEWSWIRE) — In a study published online in bioRxiv today, scientists at UCSF QBI and the University College, London reported new findings on the viral replication and pathogenesis of the B.1.1.7 U.K. coronavirus strain. In the paper titled, Evolution of Enhanced Innate Immune Evasion by the SARS-CoV-2 B.1.1.7 UK Variant, scientists described specific mutations that increase the transmissibility, enhance efficiency of host invasion, inhibit host immune response and possibly increase mortality. Importantly, these effects are connected to mutations in the virus that are not in Spike. While the B.1.1.7 variant fortunately remains sensitive to vaccine and infection-induced neutralizing antibodies, the mutations of this variant suggest [rapid] and evolved adaptation to the human host which increase the variant’s ability to survive and thrive in humans.

The study was led by the laboratories of Nevan Krogan, Ph.D., Director of the Quantitative Biosciences Institute (QBI) at the School of Pharmacy at UC San Francisco, Senior Investigator at Gladstone Institutes, and Professor Greg Towers and Dr. Clare Jolly at University College London (UCL) in London, England, among others.

“With the B.1.1.7 SARS-CoV-2 variant becoming the most prevalent coronavirus variant in the world, we sought to uncover the biological mechanisms and cellular machinery fueling its replication, transmissibility and pathogenesis,” said Dr. Krogan, who founded the QBI Coronavirus Research Group (QCRG). “We discovered that the U.K. variant has evolved rapidly with over 20 key mutations from earlier viral lineages and that these mutations, including those not in the Spike protein, have rendered this variant more infectious and capable of suppressing human host immune response. Our data reveal how the SARS-CoV-2 B.1.1.7 lineage has adapted to the host by enhancing its ability to evade the host innate immune response and increase expression of key viral innate antagonists. Furthermore, our data highlight that certain changes in protein expression levels, namely Orf9b, may have significant impact on the virus-host interaction. In identifying the key pathway and proteins responsible for pathogenesis, we have uncovered druggable targets with high therapeutic value. This has important implications for management of the ongoing pandemic.”

Professor Towers based at UCL Division of Infection & Immunity added, “We believe the B.1.1.7 variant’s ability to suppress the host immune response contributes to its transmission advantage, as has been observed for HIV, and other pandemic viruses. We hypothesize that more effective innate immune antagonism permits enhanced transmission through reduced and delayed host responses which otherwise protect cells from infection.”

Clare Jolly, Ph.D., associate professor at UCL Division of Infection & Immunity commented, “We believe our model captures the earliest interactions between the virus and airway epithelial cells, in which the virus outpaces the innate response through a combination of antagonism and evasion. These are key findings that could support identification and development of effective therapeutics against this more infectious strain.”

Remarkably, viral replication of B.1.1.7 in vitro is similar to earlier SARS-CoV-2 viral lineages. However, QBI and University of College researchers discovered striking differences with respect to the host response to these viruses. Using a combination of abundance proteomics, phosphoproteomics, mRNA sequencing as well as viral assays, they have found that B.1.1.7 isolates more effectively suppress host innate immune responses in human airway epithelial cells. Furthermore, they observed that the viral proteins Orf9b, Orf6 and N, are more highly expressed at both the RNA and protein levels in cells infected with B.1.1.7 compared to earlier SARS-CoV-2 lineages. This upregulation of Orf9b subgenomic RNA (sgRNA) expression has been linked to a mutation in B.1.1.7, suggesting a new and unique way that this virus is evolving to alter the expression of sgRNAs. Researchers found that expression of Orf9b alone suppresses innate immune responses. From previous studies conducted at QBI and published in Science, Cell and Nature, the scientists uncovered an interaction with the host protein TOM70, a mitochondrial protein required for the activation of MAVS, an RNA sensing adaptor and identified phosphorylation sites. In this present study, researchers showed that this interaction is regulated by this phosphorylation and is also required for the suppression of the innate immune response. In summary, the mutations in B.1.1.7 outside of Spike were found to allow the virus to more effectively antagonize host innate immune responses through upregulation of specific sgRNA synthesis and expression of key innate immune antagonists, increasing the likelihood of successful B.1.1.7 transmission and likely increasing in vivo replication and duration of infection. Importantly, the authors have created an experimental pipeline that is also being used to study the other variants, efforts that will allow a deeper understanding of how SARS-CoV-2 mutates to better attack its host and ultimately how it can be combatted.

About QBI: The Quantitative Biosciences Institute (QBI) is a University of California organized research unit reporting through the UCSF School of Pharmacy. QBI fosters collaborations across the biomedical and the physical sciences, seeking quantitative methods to address pressing problems in biology and biomedicine. Motivated by problems of human disease, QBI is committed to investigating fundamental biological mechanisms, because ultimately solutions to many diseases have been revealed by unexpected discoveries in the basic sciences. Learn more at qbi.ucsf.edu.

About UCSF: The University of California, San Francisco (UCSF) is exclusively focused on the health sciences and is dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care. UCSF Health, which serves as UCSF’s primary academic medical center, includes top-ranked specialty hospitals and other clinical programs, and has affiliations throughout the Bay Area. Learn more at ucsf.edu or see our Fact Sheet.

About Gladstone Institutes: To ensure our work does the greatest good, Gladstone Institutes focuses on conditions with profound medical, economic, and social impact—unsolved diseases. Gladstone is an independent, nonprofit life science research organization that uses visionary science and technology to overcome disease. It has an academic affiliation with UC San Francisco. Learn more at gladstone.org.

Authorship and funding: This work was funded by grants from the National Institute of Mental Health and the National Institute of Allergy and Infectious Diseases, both part of the National Institutes of Health; the Defense Advanced Research Projects Agency; the Center for Research for Influenza Pathogenesis; the Centers of Excellence for Influenza Research and Surveillance of the National Institute of Allergy and Infectious Diseases; the Centers of Excellence for Integrative Biology of Emerging Infectious Diseases of the Agence Nationale de la Recherche (France); F. Hoffmann-LaRoche AG; Vir Biotechnology, Centre for Integrative Biological Signalling Studies (CIBSS), European Research Council (ERC) and QCRG philanthropic donors. Shokat is a Howard Hughes Medical Institute investigator. A complete list of authors and full funding information is available in the bioRxiv paper.

About UCL – London’s Global University

UCL is a diverse community with the freedom to challenge and think differently. Our community of more than 41,500 students from 150 countries and over 12,500 staff pursues academic excellence, breaks boundaries and makes a positive impact on real world problems. We are consistently ranked among the top 10 universities in the world and are one of only a handful of institutions rated as having the strongest academic reputation and the broadest research impact. We have a progressive and integrated approach to our teaching and research – championing innovation, creativity and cross-disciplinary working. We teach our students how to think, not what to think, and see them as partners, collaborators and contributors.  For almost 200 years, we are proud to have opened higher education to students from a wide range of backgrounds and to change the way we create and share knowledge. We were the first in England to welcome women to university education and that courageous attitude and disruptive spirit is still alive today.

We are UCL.

www.ucl.ac.uk| Follow @uclnews on Twitter | Watch our YouTube channel | Listen to UCL podcasts on SoundCloud | Find out what’s on at UCL Minds | #MadeAtUCL

Find out how UCL is helping lead the global fight against COVID-19 www.ucl.ac.uk/covid-19-research

Media Contacts
UCSF QBI UCSF
Sylvia Wheeler, Wheelhouse LSA Kristen Bole, UCSF Office of Communications
swheeler@wheelhouselsa.com kristen.bole@ucsf.edu
415-317-3781
Aljanae Reynolds, Wheelhouse LSA
areynolds@wheelhouselsa.com
Gladstone Institutes
Julie Langelier, Gladstone Communications
Julie.langelier@gladstone.ucsf.edu
415-734-5000

AGC Biologics’ Heidelberg Facility to Further Supply Plasmid DNA for COVID-19 Vaccine

Seattle, June 07, 2021 (GLOBE NEWSWIRE) — AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced its partnership with BioNTech SE (Nasdaq BNTX) to further supply Plasmid DNA (pDNA) starting material for the Pfizer-BioNTech COVID-19 vaccine, at AGC’s Heidelberg, Germany facility.

“We are honored that BioNTech has entrusted us to become part of their global supply network in an effort to make the vaccine available to as many people as possible around the world,” says AGC Biologics Chief Business Officer, Mark Womack. “We are very proud of our efforts to provide our global customers with the essential materials needed to rapidly deliver vaccines in the fight against the COVID-19 pandemic.”

AGC Biologics will manufacture and supply BioNTech with pDNA starting material, an essential component of BioNTech’s mRNA-based vaccine manufacturing process.

“The team at Heidelberg is enthusiastically embracing this important project with BioNTech,” says AGC Biologics General Manager, Heidelberg, Dieter Kramer. “Every team member has a deep sense of pride in our COVID-19 teams and we look forward to supporting BioNTech in the production of their mRNA-based COVID-19 vaccine with Plasmid DNA.”

AGC Biologics’ Heidelberg facility has over 20 years of experience delivering a very wide range of microbial programs for our customers. In addition, the site is AGC’s Center of Excellence for Plasmid DNA (pDNA) production, as part of their end-to-end Cell and Gene Therapy offering.

About AGC Biologics:
AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, every step of the way. We provide world-class development and manufacture of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), viral vectors and genetically engineered cells. Our global network spans the U.S., Europe and Asia, with cGMP-compliant facilities in Seattle, Washington; Boulder, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba, Japan and we currently employ more than 1,700 employees worldwide. Our commitment to continuous innovation fosters the technical creativity to solve our clients’ most complex challenges, including specialization in fast-track projects and rare diseases. AGC Biologics is the partner of choice. To learn more, visit www.agcbio.com.

About the Vaccine:
The Pfizer-BioNTech COVID-19 Vaccine, which is based on BioNTech proprietary mRNA technology, was developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder in the European Union, and the holder of emergency use authorizations or equivalents in the United States (jointly with Pfizer), United Kingdom, Canada and other countries in advance of a planned application for full marketing authorizations in these countries.

David Self
AGC Biologics
dself@agcbio.com

 

UCSF QBI and University College, London Identify Mutations in “U.K.” Strain of Coronavirus SARS-CoV-2 Responsible for Enhanced Transmissibility and Infectivity

– Findings show key mutations and evolution of U.K. SARS-CoV-2 compared to earlier lineages account for upregulation of innate immune antagonists, which hamper immune response and allow for increased viral replication and duration of infection –

SAN FRANCISCO, Calif. and LONDON, June 07, 2021 (GLOBE NEWSWIRE) — In a study published online in bioRxiv today, scientists at UCSF QBI and the University College, London reported new findings on the viral replication and pathogenesis of the B.1.1.7 U.K. coronavirus strain. In the paper titled, Evolution of Enhanced Innate Immune Evasion by the SARS-CoV-2 B.1.1.7 UK Variant, scientists described specific mutations that increase the transmissibility, enhance efficiency of host invasion, inhibit host immune response and possibly increase mortality. Importantly, these effects are connected to mutations in the virus that are not in Spike. While the B.1.1.7 variant fortunately remains sensitive to vaccine and infection-induced neutralizing antibodies, the mutations of this variant suggest [rapid] and evolved adaptation to the human host which increase the variant’s ability to survive and thrive in humans.

The study was led by the laboratories of Nevan Krogan, Ph.D., Director of the Quantitative Biosciences Institute (QBI) at the School of Pharmacy at UC San Francisco, Senior Investigator at Gladstone Institutes, and Professor Greg Towers and Dr. Clare Jolly at University College London (UCL) in London, England, among others.

“With the B.1.1.7 SARS-CoV-2 variant becoming the most prevalent coronavirus variant in the world, we sought to uncover the biological mechanisms and cellular machinery fueling its replication, transmissibility and pathogenesis,” said Dr. Krogan, who founded the QBI Coronavirus Research Group (QCRG). “We discovered that the U.K. variant has evolved rapidly with over 20 key mutations from earlier viral lineages and that these mutations, including those not in the Spike protein, have rendered this variant more infectious and capable of suppressing human host immune response. Our data reveal how the SARS-CoV-2 B.1.1.7 lineage has adapted to the host by enhancing its ability to evade the host innate immune response and increase expression of key viral innate antagonists. Furthermore, our data highlight that certain changes in protein expression levels, namely Orf9b, may have significant impact on the virus-host interaction. In identifying the key pathway and proteins responsible for pathogenesis, we have uncovered druggable targets with high therapeutic value. This has important implications for management of the ongoing pandemic.”

Professor Towers based at UCL Division of Infection & Immunity added, “We believe the B.1.1.7 variant’s ability to suppress the host immune response contributes to its transmission advantage, as has been observed for HIV, and other pandemic viruses. We hypothesize that more effective innate immune antagonism permits enhanced transmission through reduced and delayed host responses which otherwise protect cells from infection.”

Clare Jolly, Ph.D., associate professor at UCL Division of Infection & Immunity commented, “We believe our model captures the earliest interactions between the virus and airway epithelial cells, in which the virus outpaces the innate response through a combination of antagonism and evasion. These are key findings that could support identification and development of effective therapeutics against this more infectious strain.”

Remarkably, viral replication of B.1.1.7 in vitro is similar to earlier SARS-CoV-2 viral lineages. However, QBI and University of College researchers discovered striking differences with respect to the host response to these viruses. Using a combination of abundance proteomics, phosphoproteomics, mRNA sequencing as well as viral assays, they have found that B.1.1.7 isolates more effectively suppress host innate immune responses in human airway epithelial cells. Furthermore, they observed that the viral proteins Orf9b, Orf6 and N, are more highly expressed at both the RNA and protein levels in cells infected with B.1.1.7 compared to earlier SARS-CoV-2 lineages. This upregulation of Orf9b subgenomic RNA (sgRNA) expression has been linked to a mutation in B.1.1.7, suggesting a new and unique way that this virus is evolving to alter the expression of sgRNAs. Researchers found that expression of Orf9b alone suppresses innate immune responses. From previous studies conducted at QBI and published in Science, Cell and Nature, the scientists uncovered an interaction with the host protein TOM70, a mitochondrial protein required for the activation of MAVS, an RNA sensing adaptor and identified phosphorylation sites. In this present study, researchers showed that this interaction is regulated by this phosphorylation and is also required for the suppression of the innate immune response. In summary, the mutations in B.1.1.7 outside of Spike were found to allow the virus to more effectively antagonize host innate immune responses through upregulation of specific sgRNA synthesis and expression of key innate immune antagonists, increasing the likelihood of successful B.1.1.7 transmission and likely increasing in vivo replication and duration of infection. Importantly, the authors have created an experimental pipeline that is also being used to study the other variants, efforts that will allow a deeper understanding of how SARS-CoV-2 mutates to better attack its host and ultimately how it can be combatted.

About QBI: The Quantitative Biosciences Institute (QBI) is a University of California organized research unit reporting through the UCSF School of Pharmacy. QBI fosters collaborations across the biomedical and the physical sciences, seeking quantitative methods to address pressing problems in biology and biomedicine. Motivated by problems of human disease, QBI is committed to investigating fundamental biological mechanisms, because ultimately solutions to many diseases have been revealed by unexpected discoveries in the basic sciences. Learn more at qbi.ucsf.edu.

About UCSF: The University of California, San Francisco (UCSF) is exclusively focused on the health sciences and is dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care. UCSF Health, which serves as UCSF’s primary academic medical center, includes top-ranked specialty hospitals and other clinical programs, and has affiliations throughout the Bay Area. Learn more at ucsf.edu or see our Fact Sheet.

About Gladstone Institutes: To ensure our work does the greatest good, Gladstone Institutes focuses on conditions with profound medical, economic, and social impact—unsolved diseases. Gladstone is an independent, nonprofit life science research organization that uses visionary science and technology to overcome disease. It has an academic affiliation with UC San Francisco. Learn more at gladstone.org.

Authorship and funding: This work was funded by grants from the National Institute of Mental Health and the National Institute of Allergy and Infectious Diseases, both part of the National Institutes of Health; the Defense Advanced Research Projects Agency; the Center for Research for Influenza Pathogenesis; the Centers of Excellence for Influenza Research and Surveillance of the National Institute of Allergy and Infectious Diseases; the Centers of Excellence for Integrative Biology of Emerging Infectious Diseases of the Agence Nationale de la Recherche (France); F. Hoffmann-LaRoche AG; Vir Biotechnology, Centre for Integrative Biological Signalling Studies (CIBSS), European Research Council (ERC) and QCRG philanthropic donors. Shokat is a Howard Hughes Medical Institute investigator. A complete list of authors and full funding information is available in the bioRxiv paper.

About UCL – London’s Global University

UCL is a diverse community with the freedom to challenge and think differently. Our community of more than 41,500 students from 150 countries and over 12,500 staff pursues academic excellence, breaks boundaries and makes a positive impact on real world problems. We are consistently ranked among the top 10 universities in the world and are one of only a handful of institutions rated as having the strongest academic reputation and the broadest research impact. We have a progressive and integrated approach to our teaching and research – championing innovation, creativity and cross-disciplinary working. We teach our students how to think, not what to think, and see them as partners, collaborators and contributors.  For almost 200 years, we are proud to have opened higher education to students from a wide range of backgrounds and to change the way we create and share knowledge. We were the first in England to welcome women to university education and that courageous attitude and disruptive spirit is still alive today.

We are UCL.

www.ucl.ac.uk| Follow @uclnews on Twitter | Watch our YouTube channel | Listen to UCL podcasts on SoundCloud | Find out what’s on at UCL Minds | #MadeAtUCL

Find out how UCL is helping lead the global fight against COVID-19 www.ucl.ac.uk/covid-19-research

Media Contacts
UCSF QBI UCSF
Sylvia Wheeler, Wheelhouse LSA Kristen Bole, UCSF Office of Communications
swheeler@wheelhouselsa.com kristen.bole@ucsf.edu
415-317-3781
Aljanae Reynolds, Wheelhouse LSA
areynolds@wheelhouselsa.com
Gladstone Institutes
Julie Langelier, Gladstone Communications
Julie.langelier@gladstone.ucsf.edu
415-734-5000

Nexen Tire named 2020 Best Supplier in the Competitiveness Category at First Stellantis Supplier Awards

SEOUL, South Korea, June 07, 2021 (GLOBE NEWSWIRE) — Stellantis N.V. has announced that Nexen Tire, a leading global tire manufacturer, has received the “Best Supplier Award” in the Competitiveness Category of its first annual supplier awards. The awards ceremony was held virtually on June 1, 2021 (EST) due to restrictions around COVID-19.

Stellantis N.V. is a multinational automotive manufacturer formed in 2021 following the merger between Fiat Chrysler Automobiles (FCA) and the PSA Group, and features a portfolio of brands including Jeep, Maserati, Peugeot, Fiat, Chrysler, RAM, Citroën, and others.

This is the first official awards ceremony presented by Stellantis for outstanding suppliers in 2020, who were selected based on criteria such as commercial competitiveness, innovative technology, quality, manufacturing efficiency, and supply chain.

“We are honored to receive this award,” said Travis Kang, Global CEO of Nexen Tire. “It is truly meaningful to be recognized as an exceptional supplier at Stellantis’ first awards event. We will strive to become a growing supplier to automakers worldwide.”

Nexen Tire will continuously supply tires for Stellantis platforms such as Jeep, RAM, Chrysler, and Fiat, and intends to use this award to boost its quality and technology competitiveness in marketplaces around the world.

About Nexen Tire

Nexen Tire, established in 1942, is a global tire manufacturer headquartered in South Korea. Nexen Tire, one of the world’s fastest growing tire manufacturers, currently interacts with approximately 150 countries around the world and owns four manufacturing plants – two in Korea (Yangsan and Changnyeong) and one in Qingdao, China. Another plant in Žatec, the Czech Republic has also begun operation in 2019. Nexen Tire produces tires for passenger cars, SUVs, and light trucks with advanced technology and excellence in design. Nexen Tire supplies OE tires to global car makers in various countries around the world. In 2014, the company achieved a grand slam of the world’s top 4 design awards for the first time amongst the various tire makers in the world.

For more information, please visit https://www.nexentire.com/international/

CONTACT: Sylvia Chang, sylvia.chang@pivotp.co.kr

Sophi.io Wins Two INMA Global Media Awards

TORONTO, June 07, 2021 (GLOBE NEWSWIRE) — Sophi.io, The Globe and Mail’s artificial intelligence-powered optimization and prediction platform, was announced as a winner of the International News Media Association (INMA) Global Media Awards in two categories, Best Use of Data to Automate or Personalize, and Best in Show for North America.

“The INMA Global Media Awards focus on excellence across all areas of the media business,” said Phillip Crawley, Publisher and CEO of The Globe and Mail. “I’m particularly pleased that Sophi’s fully dynamic, real-time, personalized paywall won in two categories, and that Sophi’s ground-breaking automated print laydown technology was nominated for its use with Naviga and Agderposten.”

Sophi also took second place in the categories of Best Initiative to Acquire Subscribers and Best Use of Data to Drive Subscriptions, Content, or Product Design and was shortlisted as a finalist in the following categories: Best Initiative to Register Users, and Best Product and Tech Innovation.

This year’s competition drew 644 entries from 212 news brands in 37 countries. The judges were 44 global media experts focused on breakthrough results, unique concepts, strong creativity, innovative thinking, and winner synergies across platforms.

“Great use of data with huge impact. Personalizing paywalls is key for success in the digital subscription business for news media. This entry presents more evidence why this is true,” one judge said about the paywall technology. “Their development of user- and content-propensity models is a best practice that others can learn from,” said another judge.

Another judge remarked: “Incredible Artificial Intelligence-driven personalization, and perfect embracing of the need to insert data-science talent into a news organization. Excellent impact and numbers.”

Sophi’s fully dynamic, personalized, real-time paywall uses natural language processing (NLP) to analyze both content and user behaviour to determine when to ask a reader for money or an email address, and when to leave them alone. It can optimize for multiple outcomes simultaneously (such as different bundles or price points) and also works well in cold-start situations.

Sophi is an AI platform that helps publishers identify their most valuable content and leverage it to achieve key business goals, such as maximizing subscriptions. Publishers on four continents now use Sophi’s AI/ML technology to power paywall decisions, website automation and print automation.

Sophi’s automated print laydown solution, which powers Naviga Publisher, earned an honourable mention in the Best Product and Tech Innovation category. An INMA judge commented: “Sophi – as the first of its kind – is a great example of an automated print laydown solution. Amazing to see that the work of the editor is reduced only to the selection of the content. The automation of up to 80% of newspapers’ editorial pages could be a game-changer of the print industry.”

Last year, Sophi also won the Online Journalism Award (OJA) for Technical Innovation in the Service of Digital Journalism, handed out by the Online News Association (ONA), and both the World Digital Media Award and the North American Digital Media Award awarded by The World Association of News Publishers (WAN-IFRA) in the category of Best Digital News Start-up.

About Sophi.io
Sophi.io (https://www.sophi.io) was developed by The Globe and Mail to help content publishers make important strategic and tactical decisions. It is a suite of AI and ML-powered optimization and prediction tools that includes Sophi Site Automation and Sophi Dynamic Paywall as well as Sophi Analytics, a decision-support system for content publishers. Sophi is designed to improve the metrics that matter most to your business, such as subscriber retention and acquisition, engagement, recency, frequency and volume.

Media Contact  
Jamie Rubenovitch 
Head of Marketing, Sophi 
The Globe and Mail         
416-585-3355  
jrubenovitch@globeandmail.com

Philips highlights integrated informatics solutions at virtual HIMSS & Health 2.0 European Health Conference 2021

June 7, 2021

  • Intelligent, scalable, secure and interoperable solutions seamlessly connect people, technology and data to support clinical decisions at every point of care to help improve health outcomes, patient and staff experience and reduce cost of care
  • Philips shares its vision on how digital transformation is driving the delivery of healthcare for more resilient systems

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, will showcase its latest connected, secure and scalable informatics solutions at the HIMSS and Health 2.0 European Congress, taking place virtually from June 7 – 9, 2021. Philips will showcase its deep clinical and operational expertise and innovations that foster collaboration and optimize workflows, helping clinicians and health system leaders to improve health outcomes, patient and staff experiences and reduce cost of care.

The pandemic has prompted a focus on virtual care as it showed its value as a scalable enabler to help deliver quality care when resources are limited. Care providers are looking for informatics solutions and technology infrastructures that help them to support this new model of care for both elective and acute settings. Findings of the recently published Future Health Index indicate that nearly two in three healthcare leaders are currently prioritizing investments in telehealth. The last year also underscored the need for centralized and efficient data management. To help clinicians improve patient outcomes and reduce the tremendous workload of healthcare workers, interoperability and vendor agnostic solutions are key to integrating data to drive predictive and actionable insights, and for those insights to be disseminated efficiently and effectively across the healthcare network so that the right care can be delivered at the right time, anywhere.

“The digital transformation helps to change the delivery of healthcare. To drive improvements in quality and efficiency of care, organizations must leverage integrated informatics solutions,” said Roy Jakobs, Chief Business Leader Connected Care, Philips. “At this year’s HIMSS & Health 2.0 European Health Conference, we’re excited to showcase our robust, interoperable infrastructures that unite devices, data, technology, and people. Our deep clinical and operational expertise delivers connected and secure informatics solutions that are scalable across clinical and operational departments, to help empower the people behind the data – from our cloud-enabled digital platforms, to our patient engagement, to our virtual care solutions.”

Spotlighting Philips’ solutions to deliver right care, at the right time, anywhere
During the virtual HIMSS & Health 2.0 European event, Europe’s largest virtual and digital health event, Philips will focus on the following 2021 key informatics themes: Healthcare Anywhere, Digital Transformation, Business Models, Healthcare Consumerization and Precision Care. Philips’ propositions available across these areas enable predictive, precise and virtual care, based on Philips’ secure, cloud-based HealthSuite digital platform, addressing the quadruple aim of better health outcomes, improved patient and staff experience, while lowering the cost of care; they include:

  • Acute Patient Management – continuous monitoring keeping data with the patient, distributing critical physiological trends and insights to care teams at all points of care. Philips’ acute patient management solutions bring together devices, analytics, services to allow for early detection and appropriate intervention in a secure, agile and resilient ecosystem.
  • Integrated Diagnostics – Philips Diagnostic Informatics Suite allows data curation at the point of care, fostering clinical collaboration across diagnostic and clinical service lines, as well as improving streamlined workflows and reducing variation. Data brought to meaningful insights to support a more precise diagnosis and lower total cost of ownership.
  • Virtual Care – Philips’ telehealth solutions and capabilities enable customers to extend where, when and how care is delivered –because location should never limit patient care. Virtual care can help to improve efficiency while maintaining quality of care and optimizing staff allocation and productivity through data-driven insights.

At the virtual conference, Philips will also participate in the following live and on-demand sessions:

  • Keynote Presentation on Widening our Perspective on Digital Maturity – Shez Partovi, MD, Chief Innovation and Strategy Officer, Philips, will be part of this conversation on June 7th, 4:20 – 5:00pm CET. A recording will also be available on-demand for those who cannot tune in live.
  • Best Practice Session on Digital Maturity Featuring Informed Perspectives from HIT Leaders – on-demand, 20-minute session available on the HIMSS platform during the conference.

Details on all sessions and the full program can be found here.

For more information on Philips’ solutions that will be showcased at the virtual HIMSS European conference, visit: www.philips.com/himss and follow @PhilipsLiveFrom for updates. For continued conversations around Philips’ innovation in health informatics, join us virtually or in-person at HIMSS Global taking place August 9-13, 2021 in Las Vegas, NV, USA.

For further information, please contact:

Anna Hogrebe
Philips Global Press Office
Tel: +1 416 270 67 57
E-mail: anna.hogrebe@philips.com


About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2020 sales of EUR 17.3 billion and employs approximately 77,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachment

 

Philips and Elekta deepen strategic partnership in precise and individualized oncology care

June 7, 2021

Healthcare leaders partner to streamline the path from cancer diagnosis to survivorship for better outcomes

Amsterdam, the Netherlands, and Stockholm, Sweden Royal Philips (NYSE: PHG, AEX: PHIA), and Elekta (EKTA-B.ST) today signed agreements to deepen their existing strategic partnership to advance comprehensive and personalized cancer care through precision oncology solutions.

The extended collaboration builds on the two companies’ successful cooperation in the fast-emerging field of magnetic resonance (MR)-guided adaptive radiation therapy. Through deeper cross-portfolio collaboration, Philips and Elekta will utilize their complementary capabilities to further improve patient care.

Benefiting patients throughout the care pathway
Oncology care is transforming, driven by an increasingly precise diagnosis of each tumor, and a continuously expanding range of therapy options. To fully capitalize on these opportunities, healthcare providers require integrated solutions throughout the entire cancer care pathway, from diagnosis to treatment and follow-up.

This integrated approach has the potential to provide:

  • Quicker, more accurate visualization of the tumor
  • Easier decision of optimal treatment strategy
  • Earlier assessment of therapy response
  • More effective and efficient therapy delivery

The strengthened strategic partnership intends to further deliver a superior experience in diagnosis and adaptive, personalized treatments for clinicians, shorter treatment times and more precise therapy for patients, and lowered costs of care for healthcare providers.

“To capitalize on the opportunities presented by increasingly precise diagnosis and the fast-expanding range of therapies available for cancer patients, it’s essential to provide integrated systems and solutions that provide the right insights at the right time throughout each patient’s care journey,” said Kees Wesdorp, Chief Business Leader of Precision Diagnosis at Philips. “By deepening our already-successful collaboration with Elekta, we will accelerate towards our goal of providing clear care pathways and predictable outcomes for every cancer patient. Today’s announcement is an important next step in the implementation of our strategy in precision diagnosis.”

“I expect this extended partnership to unlock opportunities that will provide better outcomes for people with cancer,” said Gustaf Salford, Elekta’s President and CEO. “Together, we’ll combine advanced informatics and image-guided radiation therapy solutions to deliver greater precision in oncology. This means easier selection by clinicians of the optimal treatment strategy and more efficient and effective therapy delivery.”

In this preferred, although non-exclusive, partnership, Elekta and Philips will leverage their capabilities to pursue integrated vendor-agnostic solutions, enhancing interoperability between the two parties’ systems and software in order to drive precision in oncology.

For further information, please contact:

Mark Groves
Philips Global Press Office
Tel: +31 631 639 916
E-mail: mark.groves@philips.com

Mattias Thorsson
Vice President, Head of Corporate Communications, Elekta
Tel: +46 70 865 8012
E-mail: mattias.thorsson@elekta.com

Cecilia Ketels
Head of Investor Relations, Elekta
Tel: +46 76 611 76 25
E-mail: cecilia.ketels@elekta.com

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2020 sales of EUR 17.3 billion and employs approximately 77,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

About Elekta
For almost five decades, Elekta has been a leader in precision radiation medicine. Our more than 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to – and benefits from – more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit elekta.com or follow @Elekta on Twitter.

Attachment